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The incidence and mortality rates of breast cancer in 
Africa have risen rapidly in recent years.[1] Women 
in sub-Saharan Africa (SSA) have some of the lowest 
incidence rates of breast cancer worldwide. However, 
the disproportionately high mortality rate reflects the 
poor survival in these developing countries.[1,2] A significant contributor 
to the observed poor survival rates seems to be an advanced stage of 
disease at first diagnosis. Predictive factors may include a lack of early 
detection programmes, poor healthcare infrastructure and suboptimal 
availability of and adherence to timely treatment.
Population growth alone will lead to an estimated 119  918 new 
cases of breast cancer by 2030 in SSA.[2] The changing reproductive 
choices of African women, particularly the postponement of child 
bearing and prolonged birth intervals, represent a shift towards 
increased breast cancer profiles and an overall burden of disease.[2] 
We aimed to investigate the stage of breast cancer at first diagnosis 
and assessed possible determinants of late-stage presentation.
Methods
Setting and patients
Chris Hani Baragwanath Academic Hospital (CHBAH), the largest 
public tertiary referral hospital in South Africa, has a catchment area 
of ~3 million people from Soweto and a surrounding region of 60 km. 
The hospital’s Batho Pele Breast Unit, a member of the International 
Breast Centres Network, has grown steadily since its inception in 2000. 
Approximately 600 outpatients visit the unit per month, with up to 25 
new breast cancer cases being diagnosed. In 2006, an electronic clinical 
data system was established to facilitate oncological decision making for 
newly diagnosed patients. For the purpose of this study, retrospective 
data of consecutively diagnosed women from October 2006 to January 
2012 were analysed. The stage and year at diagnosis (primary tumour 
(T), regional lymph nodes (N), distant metastasis (M) (TNM) staging 
was converted to Manchester staging) were documented. In our breast 
unit, the majority of patients do not undergo routine mammographic 
screening and are symptomatic at diagnosis. Patients receive standard 
diagnostic and multimodality treatment with surgery, chemotherapy, 
radiotherapy, and hormonal blockade in keeping with international 
guidelines. Treatment decisions are taken by a multidisciplinary team 
of surgeons, radiologists, medical oncologists, radiation oncologists 
and palliative care physicians.
Statistical analysis
Possible contributing factors to stage at diagnosis were assessed using 
general linear models (GLMs). Factors such as age, race, distance 
to central hospital and tumour receptor subtype were treated as 
independent variables. Stage at diagnosis was the dependent variable. 
GLMs were utilised to estimate the risk ratios for late- v. early-stage 
disease.
Results
Table 1 shows the comprehensive characteristics of breast cancer 
patients diagnosed at CHBAH during October 2006 - January 2012. 
ARTICLE 
Down-staging of breast cancer in the pre-screening 
era: Experiences from Chris Hani Baragwanath 
Academic Hospital, Soweto, South Africa
N Murugan,1 MB ChB, FCS (SA); C Dickens,2 PhD; P Pisa,3 PhD; V McCormack,2 PhD; M Joffe,1 PhD; J Jacobson,4 MBA, PhD;  
H Cubasch,1 MB ChB, FCS (SA)
1 Breast Unit, Department of Surgery, Chris Hani Baragwanath Academic Hospital, Soweto, South Africa 
2 Section of Environment and Radiation, International Agency for Research on Cancer, Lyon, France
3  MRC/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, Faculty of Health Sciences,  
University of the Witwatersrand, Johannesburg, South Africa
4 Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, USA
Corresponding author: N Murugan (nivs6ster@gmail.com)
We aimed to investigate the stage of breast cancer at first diagnosis and assess possible determinants of late-stage presentation. A consecutive 
series of women with newly diagnosed breast cancer at Chris Hani Baragwanath Academic Hospital (CHBAH), Soweto, South Africa 
were analysed. We retrospectively reviewed electronic patient records. Data were extracted for: (i) stage and year at diagnosis; (ii) travel 
distance (estimated straight-line distance from GPS-coded residential address to CHBAH); (iii) receptor subtypes; and (iv) age of patient. 
Generalised linear models were applied to estimate risk ratios for late- v. early-stage disease.
Of the patients (N=1 071) studied, the mean age was 55 years and 90% were black Africans. Patients who lived >20 km from the hospital 
(n=347; 61.8%) presented with late-stage disease (stage 3/4) compared with 50.2% who lived ≤20 km from the hospital (n=724; p=0.02). The 
majority of patients (74%) >70 years of age who lived >20 km away presented with advanced breast cancer. However, in younger patients, 
age showed no clear association with stage at presentation. Travel distance was an important predictor of later-stage disease at diagnosis, 
which was more noticeable in elderly patients. Patients with more aggressive triple-negative and HER2+ tumours presented with later-stage 
disease.
S Afr Med J 2014;104(5):380. DOI:10.7196/SAMJ.8243
CONTINUING MEDICAL EDUCATION
    May 2014, Vol. 104, No. 5
A total of 1 071 patients were included in this 
analysis. Ninety per cent were black African 
women and their mean age ± SD at diagnosis 
was 55.4±14.3 years. Overall, 54% of patients 
presented with late-stage disease (stage 3/4).
The travel distance was calculated as the 
shortest straight-line distance from the patient’s 
reported residential address to CHBAH using 
GPS-coded co-ordinates. Of the patients, 45% 
and 95% resided within 10  km and 50 km 
of the hospital, respectively. Most patients 
lived in Soweto, an average travelling distance 
of 7.5±4.0 km, with residence clusters near 
Katlehong (23.9±4.0 km), Orange Farm and 
Sebokeng (28.5±6.0 km) and Vanderbijlpark 
(47.5±2.7 km) (Fig. 1).
Of the patients who lived >20  km from 
the hospital, 347 (61.8%) presented with 
late-stage disease (stage 3/4) compared 
with 724 (50.2%) who lived within 20 km 
(p=0.02).[3] Advanced stage at diagnosis was 
particularly common (74%) in patients >70 
years living >20  km away. Notably, there 
were few elderly patients >70 years from 
distances >20 km in this series. This could 
indicate that these especially vulnerable 
patients cannot reach the hospital. The 
relative distribution of travel distances 
within 50 km of CHBAH Breast Clinic for 
breast cancer patients <50 years (n=384), 
50 - 69 years (n=437) and ≥70 years (n=176) 
are shown in Fig. 2.
In this series, 67% of tumours were 
oestrogen- and/or progesterone-positive, 
with only 21% being of the poorer prognosis 
triple-negative subtype. As expected, patients 
with more aggressive triple-negative and 
HER2+ tumours presented with later-stage 
disease (Fig. 3).
The majority of patients were referred 
by primary healthcare clinics, with an esti-
mated 18% being self-referrals. There was 
an encouraging down-staging of disease 
(i.e. diagnosis at an earlier stage) observed 
when stage at diagnosis was plotted against 
year at diagnosis. From 2008 onwards, 
compared with baseline 2006 - 2007 data, the 
proportion of late-stage disease decreased 
from 71% to 48% (Fig. 4).
No significant correlation between stage 
and age was observed, with the exception 
of the very old who presented with more 
advanced disease (Fig. 5).
Discussion
The current study investigated stage of breast 
cancer at initial diagnosis and assessed 
the possible determinants of late-stage 
presentation. The main findings showed 
that among the 1 071 patients analysed the 
mean age was 55 years and 90% were black 
Africans. Of the patients who lived >20 km 
from the hospital, 347 (61.8%) presented 
with late-stage disease (stage 3/4) compared 
with 50.2% who lived ≤20 km from the 
hospital (n=724; p=0.02). The majority of 
patients >70 years (74%) who lived >20 km 
away, presented with advanced breast cancer. 
We assume that many elderly patients cannot 
reach the hospital.
Stage at diagnosis, particularly in 
developing countries, is a strong predictor of 
breast cancer survival,[3] and understanding 
the determinants of delay in diagnosis is 
essential for controlling this increasing 
burden. The current study provides evidence 
for the potential down-staging of breast 
cancer in a South African peri-urban 
setting in the absence of population-wide 
mammographic screening. The observed 
decline in the proportion of late-stage breast 
cancer over this 5-year period suggests that 
down-staging was observed in the absence 
Table 1. Characteristics of breast cancer patients (N=1 071) diagnosed at Chris Hani 
Baragwanath Academic Hospital from October 2006 to January 2012
Demographic characteristics Category N (%)
Age at diagnosis (years) <40 157 (14.7)
40 - 49 253 (23.6)
50 - 59 274 (25.6)
60 - 69 200 (18.7)
≥70 187 (17.5)
Year at diagnosis 2006 - 2007 167 (15.6)
2008 - 2009 414 (38,7)
2010 - 2012 490 (45.8)
Race Black 964 (90.0)
White 43 (4)
Coloured 42 (3.9)
Indian/Asian 18 (1.7)
Distance travelled (km) <5 183 (17.1)
5 - 9.9 299 (27.9)
10 - 19.9 242 (22.6)
20 - 29.9 188 (17.6)
30 - 39.9 61 (5.7)
>40 98 (9.6)
Referral source: limited cohort 
(n=493)
Primary clinic 243 (49.3)
Secondary hospital 107 (21.7)
Local doctor 57 (11.6)
Self-referral 86 (17.5)
Stage of disease at presentation Stage 1 53 (5)
Stage 2 431 (41)
Stage 3 480 (45.7)
Stage 4 87 (8.3)
Receptor status ER and/or PR+ve 628 (66.6)
ER–ve and PR–ve 315 (33.4)
HER2+ve 235 (26)
HER2–ve 668 (74)
ER–ve, PR–ve, HER2–ve 193 (21.5)
ER = oestrogen receptor; PR = progesterone receptor.
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of routine screening, probably owing to 
improved access and heightened awareness.
South Africa is undergoing rapid transi-
tion characterised by a high prevalence 
of HIV infection and the emergence of 
non-communicable diseases, including 
cancer. The majority of patients cannot 
afford private medical care and are treated 
in the state healthcare system, making them 
vulnerable to all the failings of the existing 
infrastructure. The journey of a woman with 
breast cancer in South Africa varies greatly 
from patient to patient. Typically, in the 
public sector, it involves the woman noticing 
symptoms and taking the initiative to seek 
help in the healthcare system. She often has 
to navigate past multiple healthcare levels 
before reaching a histological diagnosis and 
receiving definitive care.
CHBAH is a tertiary-level public sector 
hospital and, as such, is the third tier in 
the hierarchy of the healthcare system. 
Primary healthcare clinics and local general 
practitioners are usually the first tier of this 
referral structure, followed by secondary 
level district hospitals.[4] Some patients (18% 
in this study) choose to bypass the system 
and present themselves directly to hospital, 
facilitated by the fact that the Breast Clinic 
at CHBAH is a walk-in clinic.
Delays in reaching CHBAH may be due 
to patient and health-system factors. At 
the patient level, personal (awareness) and 
sociocultural and economic factors may lead 
to delays. Our study showed that a travel 
distance >20 km from the Breast Clinic was 
a significant predictor of the stage of disease 
at first presentation. Distance-associated 
hurdles adversely affected older patients. For 
patients who had to travel greater distances, 
the financial burden associated with 
travelling to hospital represented a significant 
barrier to optimal care.[5] The minimum 
weekly wage for an average domestic worker 
in South Africa is approximately R320. A 
round trip to hospital may consume 5 - 14% 
of a woman’s weekly income, before loss 
of working hours is taken into account. 
In addition, many of these women have 
responsibilities as primary family caregivers 
and therefore have to make arrangements for 
child/grandchild minding prior to clinic or 
hospital visits.
Increased travel distance is also likely 
to affect the post-diagnosis experience of 
a breast cancer patient as it may influence 
treatment access and compliance. Repeated 
cycles of chemotherapy, radiotherapy and 
post-surgical follow-up visits invariably have 
a significant financial impact on the patient, 
and travel-associated barriers may increase 
as the patient becomes weaker.
Another notable finding was that 66.6% of 
the patients were diagnosed with oestrogen 
and/or progesterone receptor-positive 
tumours, with only 21.5% of cancers being 
triple-negative. The predominance of these 
luminal A and B tumours, with a better 
prognosis, and the strong down-staging 
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Fig. 2. Relative distribution of travel distances within 50 km of Chris Hani Baragwanath Academic 
Hospital Breast Clinic for breast cancer patients <50 years (n=384), 50 - 69 years (n=437) and ≥70 
years (n=176).
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Fig. 1. Residential locations of breast cancer patients diagnosed at Chris Hani Baragwanath Academic 
Hospital during 2006 - 2012 with straight-line distances to the Breast Clinic (<5 km to hospital (17.1%), 
5 - 9.9 km (27.9%), 10 - 19.9 km (22.6%), 20 - 29.9 km (17.6%), 30 - 39.9 km (5.7%)).
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trend observed over the study period, 
suggest that late-stage diagnosis in similar 
settings is driven to a greater extent by non-
biological determinants rather than by an 
aggressive, rapidly growing tumour.
It is important to acknowledge the socio-
cultural factors and personal barriers to 
presentation, especially when considering 
the proximally located patients with more 
immediate access to CHBAH, who presented 
with advanced disease. Understanding the 
underlying causes of these additional barriers 
is essential if there is to be a feasible possibility 
of initiating improved strategies. Lack of 
education, lack of knowledge of symptoms, 
lack of breast awareness, fear of treatment 
and cultural beliefs may all be detrimental 
contributing factors in our setting. There might 
also be an inherent distrust of conventional 
western treatment thought to interfere with 
indigenous remedies. Additionally, primary 
healthcare facilities are generally perceived as 
having long waiting times, ineffective service 
and inexperienced staff.
In conclusion, breast awareness in general 
has significantly increased in the past few 
years, with various media campaigns with 
regard to breast cancer, including walkathons 
and articles in women’s magazines. This may 
partly account for breast cancer down-staging 
in the absence of population-wide routine 
mammographic screening. In addition, the 
CHBAH Breast Unit is easily accessible, with 
an open-door walk-in policy. Understanding 
the various factors that contribute to 
diagnostic delay is particularly relevant in 
the South African public healthcare sector 
and may enable interventions, ensuring that 
more cancers are diagnosed at an earlier 
stage and improved survival. 
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Fig. 5. Stage distribution by age at diagnosis (1 = stage 1; 2 = stage 2; 3 = stage 3; and 4 = stage 4).
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Fig. 4. Stage distribution by year (2006 - 2007; 2008 - 2010; 2010 - 2012) at diagnosis (1 = stage 1; 2 = 
stage 2; 3 = stage 3; and 4 = stage 4).
Luminal A Luminal B HER2+ Basal
10
0
80
60
40
20
0
%
1 2
3 4
Fig. 3. Stage distribution by tumour receptor subtype (1 = stage 1; 2 = stage 2; 3 = stage 3; and 4 = 
stage 4).
